iPSC Cell Therapy

Business news, market intelligence, and global industry analysis.

The Latest

Can selective Bb inhibition give NovelMed Therapeutics an edge in the multibillion-dollar PNH drug market?

Can fewer infusions improve adherence in Fabry disease enzyme replacement therapy?

CVS stock slips as Aetna settles Medicare Advantage diagnosis code fraud case for $117.7m

What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)

Fate Therapeutics unveils ACR 2025 results: FT819 off-the-shelf CAR T drives immune remodeling in lupus

Discover how Fate Therapeutics’ FT819 off-the-shelf CAR T therapy is reshaping lupus treatment through durable immune remodeling and long-term remission.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

October 26, 2025